Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
japanese encephalitis chimeric virus vaccine
- Development stage
- Phase 4
- Lead developer
- Parent
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Japanese encephalitis chimeric virus vaccine is a live, attenuated recombinant viral vaccine designed to prevent infection by the Japanese encephalitis virus (JEV), a leading cause of viral encephalitis in Asia. The most widely used formulation, known as Imojev (JE-CV or ChimeriVax-JE), is constructed by replacing the genes encoding two structural proteins (prM and E) of the yellow fever 17D virus with those from an attenuated strain of JEV (SA14-14-2). This design induces protective humoral and cellular immunity against JEV. The primary indication is prevention of Japanese encephalitis in endemic regions or for travelers to these areas. Imojev provides strong initial immunity after a single dose, with seropositivity exceeding 90% up to 10 years post-vaccination, though waning immunity may occur in some individuals over time[2][3][4][5].
- Brand names
- Imojev
- Other names
- live recombinant Japanese encephalitis chimeric vaccineYFV-17D-based chimeric Japanese encephalitis vaccineYFV17D-based chimeric Japanese encephalitis vaccineYFV 17D-based chimeric Japanese encephalitis vaccineyellow fever-Japanese encephalitis chimeric vaccine
02
Targets
Japanese encephalitis virus envelope protein (E protein)Yellow fever virus 17D nonstructural protein (YFV 17D NS protein)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on japanese encephalitis chimeric virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on japanese encephalitis chimeric virus vaccine.